Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer

Inclusion Criteria:

* patients with histologically proven seminomatous or non-seminomatous germ cell cancer
* patients with relapse within 8 weeks after at least 2 different cisplatin- based regimens or
* patients with disease progression or relapse after salvage high-dose chemotherapy or patients with disease progression during cisplatin-based chemotherapy or patients with contraindications for other aggressive chemotherapy
* measurable disease
* Life expectancy of greater than 3 months
* Karnofsky Performance status \> 60
* age \> 18
* adequate organ function
* Resolution of acute toxic effects of prior radiotherapy, surgical procedure or chemotherapy to NCI CTCAE Version 3.0 \<= grade 1.
* Left ventricular ejection fraction (LVEF) \>= lower limit of normal (LLN) as defined by the institution performing the scan as assessed by multigated acquisition (MUGA) scan or echocardiography
* Signed and dated informed consent document
* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion Criteria:

* Acute infection
* Uncontrolled intercurrent illness
* Patients with a history of other active malignancy in the past 5 years (with the exception of adequately treated cervical carcinoma in situ and non melanomatous skin cancers) are excluded.
* Interval from last chemotherapy \< 3 weeks.
* Simultaneous radiation of the only target lesion
* NCI CTCAE grade 3 hemorrhage \< 4 weeks of starting the study treatment
* Patients must not be on therapeutic anticoagulation.
* Major surgery or radiation therapy within \< 4 weeks of starting the study treatment.
* History of or known brain metastases, spinal cord compression, or carcinomatous meningitis, or evidence of brain or leptomeningeal disease
* Any of the following within the 12 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism.
* Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication.
* Ongoing cardiac arrhythmias of NCI CTCAE grade \>= 2, atrial fibrillation of any grade, or prolongation of the QTc interval to \>500 msec on baseline EKG.
* Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
* Hypertension that cannot be controlled by medications (\>150/100 mm Hg despite optimal medical therapy).
* Current treatment on another clinical trial.